Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапия тела. Часть ІІ. Рак молочной железы

Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапия тела. Часть ІІ. Рак молочной железы

Автор: Паньшин Г.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзор

Статья в выпуске: 4 т.23, 2023 года.

Бесплатный доступ

Метастатический рак молочной железы исторически считался неизлечимым заболеванием. Радиотерапия (РТ) традиционно использовалась только для паллиативного лечения симптомов, вызванных метастатическими очагами. Однако в последние годы в онкологической практике введено понятие олигометастатического заболевания (ОМЗ) как клинического сценария с наличием ограниченного числа метастазов (≤ 5) и поражением ограниченного числа органов (≤ 3) на фоне контролируемого первичного опухолевого процесса. Предполагается, что при ОМЗ местно-регионарное лечение первичной опухоли и противоопухолевая терапия, направленная на очаги метастазирования с использованием хирургического метода или РТ, могут, в целом, улучшить исходы специального лечения. Недавние исследования показали, что не все пациенты с метастатическим раком молочной железы имеют одинаковый прогноз основного заболевания. Возможен отбор пациенток с хорошими прогностическими признаками, такими например, как возраст менее 55 лет, наличие положительных гормональных рецепторов, ограниченное число метастазов в кости или печени, опухоль низкой степени злокачественности, удовлетворительное общее состояние, длительный безрецидивный период после первоначально проведенного противоопухолевого лечения (> 12 мес.) и качественный .ответ на системную терапию. Наличие таких прогностических признаков может обеспечить максимальную эффективность от радикального лечения всех опухолевых очагов.Данный обзор является продолжением цикла обзоров, посвященных современному состоянию вопроса о роли дистанционной стереотаксической абляционной радиотерапии тела (ДСАРТТ) при олигометастатической болезни (ОМБ). В обзоре будет обсуждаться концепция олигометастазов и будет представлена имеющаяся в открытой печати актуальная информация об использовании ДСАРТТ при олигометастатическом раке молочной железы.

Еще

Олигометастатический рак молочной железы, дистанционная стереотаксическая абляционная ралиотерапия тела, локорегионарное лечение

Короткий адрес: https://sciup.org/149145017

IDR: 149145017

Список литературы Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапия тела. Часть ІІ. Рак молочной железы

  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590.
  • Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, et al.; European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group. Breast carcinoma survival in Europe and the United States. Cancer. 2004 Feb 15;100(4):715-722. doi: 10.1002/cncr.20038.
  • Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, Xie X. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018 Nov 5;10:5329-5338. doi: 10.2147/CMAR.S176763.
  • Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, et al. European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group. Breast carcinoma survival in Europe and the United States. Cancer. 2004 Feb 15;100(4):715-722. doi: 10.1002/cncr.20038.
  • Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018 Aug;170(3):647-656. doi: 10.1007/s10549-018-4796-9.
  • Bitencourt AGV, Andrade WP, da Cunha RR, Conrado JLFA, Lima ENP, Barbosa PNVP, Chojniak R. Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans. Radiol Bras. 2017 Jul-Aug;50(4):211-215. doi: 10.1590/0100-3984.2015-0232.
  • Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8-10. doi: 10.1200/JCO.1995.13.1.8.
  • Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149.
  • Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818.
  • Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol. 2018 Jan;126(1):177-180. doi: 10.1016/j.radonc.2017.08.032.
  • Gultekin M, Yazici O, Eren G, Yuce D, Aksoy S, Ozisik Y, et al. Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma. Breast. 2014 Dec;23(6):775-783. doi: 10.1016/j.breast.2014.08.008.
  • Le Scodan R, Stevens D, Brain E, Floiras JL, Cohen-Solal C, De La Lande B, et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol. 2009 Mar 20;27(9):1375-1381. doi: 10.1200/JCO.2008.19.5396.
  • Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother Oncol. 2019 Feb;131:45-51. doi: 10.1016/j.radonc.2018.11.022.
  • Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007 Sep 1;110(5):973-979. doi: 10.1002/cncr.22867.
  • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450.
  • Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, et al. Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Front Oncol. 2021 Mar 17;11:640690. doi: 10.3389/fonc.2021.640690.
  • Melchior NM, Sachs DB, Gauvin G, Chang C, Wang CE, Sigurdson ER, et al. Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy? Cancer Med. 2020 Apr;9(8):2742-2751. doi: 10.1002/cam4.2912.
  • von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al.; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017.
  • Yang F, Huang X, Sun C, Li J, Wang B, Yan M, et al. Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population. BMC Cancer. 2020 Mar 29;20(1):255. doi: 10.1186/s12885-020-6639-4.
  • Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X.
  • Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, et al. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (Basel). 2019 Nov 20;11(12):1826. doi: 10.3390/cancers11121826.
  • Moreno-Vega A, Vega-Riveroll L, Ayala T, Peralta G, Torres-Martel JM, Rojas J, et al. Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study. Nutrients. 2019 Jul 17;11(7):1623. doi: 10.3390/nu11071623.
  • Moreno-Vega A, Vega-Riveroll L, Ayala T, Peralta G, Torres-Martel JM, Rojas J, et al. Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study. Nutrients. 2019 Jul 17;11(7):1623. doi: 10.3390/nu11071623.
  • Galván Morales MA, Barrera Rodríguez R, Santiago Cruz JR, Teran LM. Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules. 2020 Dec 2;25(23):5686. doi: 10.3390/molecules25235686.
  • Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Aug;14(8):2197-2205. doi: 10.1200/JCO.1996.14.8.2197.
  • Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015 Apr 28;112(9):1445-1451. doi: 10.1038/bjc.2015.127.
  • Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, et al. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol. 2014 Mar;25(3):633-638. doi: 10.1093/annonc/mdt539.
  • van Ommen-Nijhof A, Steenbruggen TG, Schats W, Wiersma T, Horlings HM, Mann R, et al. Prognostic factors in patients with oligometastatic breast cancer - A systematic review. Cancer Treat Rev. 2020 Dec;91:102114. doi: 10.1016/j.ctrv.2020.102114.
  • Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, de Souza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1.
  • Szturz P, Vermorken JB. Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond. Cancers (Basel). 2021 May 21;13(11):2518. doi: 10.3390/cancers13112518.
  • Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013 Oct;141(3):507-514. doi: 10.1007/s10549-013-2711-y.
  • den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017 Feb;161(3):549-556. doi: 10.1007/s10549-016-4080-9.
  • AlSendi M, O'Reilly D, Zeidan YH, Kelly CM. Oligometastatic breast cancer: Are we there yet? Int J Cancer. 2021 Oct 15;149(8):1520-1528. doi: 10.1002/ijc.33693.
  • Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.
  • Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, et al. Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. J Cancer Res Clin Oncol. 2017 Sep;143(9):1701-1712. doi: 10.1007/s00432-017-2428-0.
  • Barberi V, Pietragalla A, Franceschini G, Marazzi F, Paris I, Cognetti F, et al. Oligometastatic Breast Cancer: How to Manage It? J Pers Med. 2021 Jun 9;11(6):532. doi: 10.3390/jpm11060532.
  • Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650. doi: 10.1371/journal.pone.0028650.
  • Zengel B, Kilic M, Tasli F, Simsek C, Karatas M, Ozdemir O, et al. Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes. Sci Rep. 2021 Oct 11;11(1):20175. doi: 10.1038/s41598-021-99726-7.
  • Gera R, Chehade HELH, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis. Sci Rep. 2020 Feb 19;10(1):2952. doi: 10.1038/s41598-020-59908-1.
  • Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015 Oct;16(13):1380-8. doi: 10.1016/S1470-2045(15)00135-7.
  • Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol. 2018 Oct;25(11):3141-3149. doi: 10.1245/s10434-018-6494-6.
  • Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, et al.; ABCSG. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.
  • Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, et al. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol. 2012 Oct;42(10):970-3. doi: 10.1093/jjco/hys120.
  • Khan SA, DesJardin ESM. Readdressing the Role of Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer. Cancer Treat Res. 2018;173:73-88. doi: 10.1007/978-3-319-70197-4_6.
  • ClinicalTrials.gov. NCT02089100. Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer (STEREO-SEIN)
  • ClinicalTrials.gov. NCT 03750396. Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR).
  • ClinicalTrials.gov. NCT02364557. Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival.
  • Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.
  • Chmura SJ, Winter KA, Al-Hallaq HA, Borges VF, Jaskowiak NT, Matuszak M, et al. NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557). Journal of Clinical Oncology. 2019;37:TPS1117–TPS1117. American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2019.37.15_suppl.tps1117.
  • Bourgier C. Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer (STEREO-SEIN). accessed 2 Aug 2023]. In: ClinicalTrials.gov [Internet]. ClinicalTrials.gov Identifier: N02089100. Available from: https://clinicaltrials.gov/ct2/show/NCT02089100.
  • Miyata M, Ohguri T, Yahara K, Yamaguchi S, Imada H, Korogi Y. Salvage radiotherapy for second oligo-recurrence in patients with breast cancer. J Radiat Res. 2018 Jan 1;59(1):58-66. doi: 10.1093/jrr/rrx066.
  • Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol. 2018 Jan;126(1):177-180. doi: 10.1016/j.radonc.2017.08.032.
  • Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother Oncol. 2019 Feb;131:45-51. doi: 10.1016/j.radonc.2018.11.022.
  • David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, Loi S, Siva S. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast. 2020 Feb;49:55-62. doi: 10.1016/j.breast.2019.10.016.
  • Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149.
  • Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012 Jul;19(3):218-37. doi: 10.1007/s12282-012-0347-0.
  • Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009 Jun;115(3):601-608. doi: 10.1007/s10549-008-0157-4.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp